Talapro-2: Part 2 (P2) Of The Placebo-Controlled Phase 3 Study Of Talazoparib (Tala) With Enzalutamide (Enza) In Metastatic Castration-Resistant Prostate Cancer (Mcrpc).

Neeraj Agarwal,Neal D. Shore,Curtis Dunshee,Lawrence Ivan Karsh,Beth Sullivan,Nicola Di Santo,Mohamed Elmeliegy,Michelle Casey,Ruben G.W. Quek,Akos Czibere,Karim Fizazi

JOURNAL OF CLINICAL ONCOLOGY（2019）

引用 1|浏览3

暂无评分

摘要

TPS337Background: ENZA is approved to treat men with CRPC. TALA is a poly(ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP1/PARP2 and traps PARP on DNA, preventing DNA damage repair (DDR)...

查看译文

关键词

Enzalutamide,Talazoparib,PARP1,Prostate cancer,Poly ADP ribose polymerase,Polymerase,Phases of clinical research,Cancer research,Placebo,Medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要